KIT and Hepatic fibrosis: In agreement with the results based on CD34 and PDGFR-α double labelling, Figures3–5 also indicated that the number of TCs were severely reduced in liver fibrosis determined by CD34 and PDGFR-β, CD34 and vimentin, and CD34 and c-kit/CD117 double labelling.